-+ 0.00%
-+ 0.00%
-+ 0.00%

Sinqi Pharmaceutical (300573.SZ): SQ-25042 intraocular injection solution approved for clinical trials

Zhitongcaijing·11/20/2026 08:01:08
Listen to the news

Zhitong Finance App News, Sinqi Pharmaceutical (300573.SZ) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration regarding the SQ-25042 intraocular injection solution. SQ-25042 intraocular injection solution is a fusion protein independently developed by the company. It is a class 1 innovative drug for therapeutic biological products. It is clinically intended to treat neovascularization (wet) age-related macular degeneration (NaMD), diabetic macular edema (DME), and macular oedema secondary to retinal vein occlusion (RVO).